Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jan;39(1):1–8. doi: 10.1128/aac.39.1.1

Resistance of Candida species to fluconazole.

J H Rex 1, M G Rinaldi 1, M A Pfaller 1
PMCID: PMC162475  PMID: 7695288

Full Text

The Full Text of this article is available as a PDF (209.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrahamsen T. G., Widing E., Glomstein A., Gaustad P. Disseminated fungal disease resistant to fluconazole treatment in a child with leukemia. Scand J Infect Dis. 1992;24(3):391–393. doi: 10.3109/00365549209061349. [DOI] [PubMed] [Google Scholar]
  2. Akova M., Akalin H. E., Uzun O., Gür D. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis. 1991 Jul;10(7):598–599. doi: 10.1007/BF01967286. [DOI] [PubMed] [Google Scholar]
  3. Akova M., Akalin H. E., Uzun O., Hayran M., Tekuzman G., Kansu E., Aslan S., Telatar H. Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome. Clin Infect Dis. 1994 Mar;18(3):298–304. doi: 10.1093/clinids/18.3.298. [DOI] [PubMed] [Google Scholar]
  4. Anaissie E. J., Karyotakis N. C., Hachem R., Dignani M. C., Rex J. H., Paetznick V. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis. 1994 Aug;170(2):384–389. doi: 10.1093/infdis/170.2.384. [DOI] [PubMed] [Google Scholar]
  5. Ansari A. M., Gould I. M., Douglas J. G. High dose oral fluconazole for oropharyngeal candidosis in AIDS. J Antimicrob Chemother. 1990 Apr;25(4):720–721. doi: 10.1093/jac/25.4.720. [DOI] [PubMed] [Google Scholar]
  6. Arilla M. C., Carbonero J. L., Schneider J., Regúlez P., Quindós G., Pontón J., Cisterna R. Vulvovaginal candidiasis refractory to treatment with fluconazole. Eur J Obstet Gynecol Reprod Biol. 1992 Mar 23;44(1):77–80. doi: 10.1016/0028-2243(92)90317-r. [DOI] [PubMed] [Google Scholar]
  7. Bailey E. M., Krakovsky D. J., Rybak M. J. The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy. 1990;10(2):146–153. [PubMed] [Google Scholar]
  8. Bailly M. P., Boibieux A., Biron F., Durieu I., Piens M. A., Peyramond D., Bertrand J. L. Persistence of Cryptococcus neoformans in the prostate: failure of fluconazole despite high doses. J Infect Dis. 1991 Aug;164(2):435–436. doi: 10.1093/infdis/164.2.435. [DOI] [PubMed] [Google Scholar]
  9. Banerjee S. N., Emori T. G., Culver D. H., Gaynes R. P., Jarvis W. R., Horan T., Edwards J. R., Tolson J., Henderson T., Martone W. J. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med. 1991 Sep 16;91(3B):86S–89S. doi: 10.1016/0002-9343(91)90349-3. [DOI] [PubMed] [Google Scholar]
  10. Barchiesi F., Colombo A. L., McGough D. A., Fothergill A. W., Rinaldi M. G. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1994 Jul;38(7):1530–1533. doi: 10.1128/aac.38.7.1530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Barchiesi F., Giacometti A., Arzeni D., Branchesi P., Crescenzi G., Ancarani F., Scalise G. Fluconazole and ketoconazole in the treatment of oral and esophageal candidiasis in AIDS patients. J Chemother. 1992 Dec;4(6):381–386. doi: 10.1080/1120009x.1992.11739196. [DOI] [PubMed] [Google Scholar]
  12. Barchiesi F., Morbiducci V., Ancarani F., Scalise G. Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol. 1993 Jul;9(4):455–456. doi: 10.1007/BF00157408. [DOI] [PubMed] [Google Scholar]
  13. Bart-Delabesse E., Boiron P., Carlotti A., Dupont B. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol. 1993 Nov;31(11):2933–2937. doi: 10.1128/jcm.31.11.2933-2937.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Berry A. J., Rinaldi M. G., Graybill J. R. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother. 1992 Mar;36(3):690–692. doi: 10.1128/aac.36.3.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Bignardi G. E., Savage M. A., Coker R., Davis S. G. Fluconazole and Candida krusei infections. J Hosp Infect. 1991 Aug;18(4):326–327. doi: 10.1016/0195-6701(91)90193-c. [DOI] [PubMed] [Google Scholar]
  16. Boken D. J., Swindells S., Rinaldi M. G. Fluconazole-resistant Candida albicans. Clin Infect Dis. 1993 Dec;17(6):1018–1021. doi: 10.1093/clinids/17.6.1018. [DOI] [PubMed] [Google Scholar]
  17. Brammer K. W., Farrow P. R., Faulkner J. K. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S318–S326. doi: 10.1093/clinids/12.supplement_3.s318. [DOI] [PubMed] [Google Scholar]
  18. Cameron M. L., Schell W. A., Bruch S., Bartlett J. A., Waskin H. A., Perfect J. R. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1993 Nov;37(11):2449–2453. doi: 10.1128/aac.37.11.2449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Case C. P., MacGowan A. P., Brown N. M., Reeves D. S., Whitehead P., Felmingham D. Prophylactic oral fluconazole and candida fungaemia. Lancet. 1991 Mar 30;337(8744):790–790. doi: 10.1016/0140-6736(91)91406-k. [DOI] [PubMed] [Google Scholar]
  20. Coker R. J., Harris J. R. Failure of fluconazole treatment in cryptococcal meningitis despite adequate CSF levels. J Infect. 1991 Jul;23(1):101–103. doi: 10.1016/0163-4453(91)94283-p. [DOI] [PubMed] [Google Scholar]
  21. Colville A., Wale M. C. Fluconazole or amphotericin for candidaemia in non-neutropenic patients? Lancet. 1991 Jun 29;337(8757):1605–1606. doi: 10.1016/0140-6736(91)93299-o. [DOI] [PubMed] [Google Scholar]
  22. Dan M., Priel I. Failure of fluconazole therapy for sternal osteomyelitis due to Candida albicans. Clin Infect Dis. 1994 Jan;18(1):126–127. doi: 10.1093/clinids/18.1.126. [DOI] [PubMed] [Google Scholar]
  23. Dupouy-Camet J., Paugam A., Di Donato C., Viguié C., Vicens I., Volle P. J., Tourte-Schaefer C. Résistance au fluconazole en milieu hospitalier. Concordance entre la résistance de Candida albicans in vitro et l'échec thérapeutique. Presse Med. 1991 Sep 14;20(28):1341–1341. [PubMed] [Google Scholar]
  24. Espinel-Ingroff A., Kerkering T. M., Goldson P. R., Shadomy S. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol. 1991 Jun;29(6):1089–1094. doi: 10.1128/jcm.29.6.1089-1094.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Evans T. G., Mayer J., Cohen S., Classen D., Carroll K. Fluconazole failure in the treatment of invasive mycoses. J Infect Dis. 1991 Dec;164(6):1232–1235. doi: 10.1093/infdis/164.6.1232. [DOI] [PubMed] [Google Scholar]
  26. Fan-Havard P., Capano D., Smith S. M., Mangia A., Eng R. H. Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother. 1991 Nov;35(11):2302–2305. doi: 10.1128/aac.35.11.2302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Fox R., Neal K. R., Leen C. L., Ellis M. E., Mandal B. K. Fluconazole resistant candida in AIDS. J Infect. 1991 Mar;22(2):201–204. doi: 10.1016/0163-4453(91)91767-r. [DOI] [PubMed] [Google Scholar]
  28. Glatt A. E., Chirgwin K., Landesman S. H. Current concepts. Treatment of infections associated with human immunodeficiency virus. N Engl J Med. 1988 Jun 2;318(22):1439–1448. doi: 10.1056/NEJM198806023182206. [DOI] [PubMed] [Google Scholar]
  29. Goldman M., Pottage J. C., Jr, Weaver D. C. Candida krusei fungemia. Report of 4 cases and review of the literature. Medicine (Baltimore) 1993 May;72(3):143–150. [PubMed] [Google Scholar]
  30. Graninger W., Presteril E., Schneeweiss B., Teleky B., Georgopoulos A. Treatment of Candida albicans fungaemia with fluconazole. J Infect. 1993 Mar;26(2):133–146. doi: 10.1016/0163-4453(93)92761-k. [DOI] [PubMed] [Google Scholar]
  31. Greenwood D. In vitro veritas? Antimicrobial susceptibility tests and their clinical relevance. J Infect Dis. 1981 Oct;144(4):380–385. doi: 10.1093/infdis/144.4.380. [DOI] [PubMed] [Google Scholar]
  32. Harris S. C., Wallace J. E., Foulds G., Rinaldi M. G. Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chemother. 1989 May;33(5):714–716. doi: 10.1128/aac.33.5.714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Heinic G. S., Stevens D. A., Greenspan D., MacPhail L. A., Dodd C. L., Stringari S., Strull W. M., Hollander H. Fluconazole-resistant Candida in AIDS patients. Report of two cases. Oral Surg Oral Med Oral Pathol. 1993 Dec;76(6):711–715. doi: 10.1016/0030-4220(93)90039-7. [DOI] [PubMed] [Google Scholar]
  34. High K. P., Quagliarello V. J. Yeast perinephric abscess: report of a case and review. Clin Infect Dis. 1992 Jul;15(1):128–133. doi: 10.1093/clinids/15.1.128. [DOI] [PubMed] [Google Scholar]
  35. Hitchcock C. A., Pye G. W., Troke P. F., Johnson E. M., Warnock D. W. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother. 1993 Sep;37(9):1962–1965. doi: 10.1128/aac.37.9.1962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Hitchcock C. A. Resistance of Candida albicans to azole antifungal agents. Biochem Soc Trans. 1993 Nov;21(4):1039–1047. doi: 10.1042/bst0211039. [DOI] [PubMed] [Google Scholar]
  37. Horsburgh C. R., Jr, Kirkpatrick C. H. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med. 1983 Jan 24;74(1B):23–29. doi: 10.1016/0002-9343(83)90511-9. [DOI] [PubMed] [Google Scholar]
  38. Johnson E. M., Richardson M. D., Warnock D. W. In-vitro resistance to imidazole antifungals in Candida albicans. J Antimicrob Chemother. 1984 Jun;13(6):547–558. doi: 10.1093/jac/13.6.547. [DOI] [PubMed] [Google Scholar]
  39. Kitchen V. S., Savage M., Harris J. R. Candida albicans resistance in AIDS. J Infect. 1991 Mar;22(2):204–205. doi: 10.1016/0163-4453(91)91789-z. [DOI] [PubMed] [Google Scholar]
  40. Korting H. C., Ollert M., Georgii A., Fröschl M. In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol. 1988 Dec;26(12):2626–2631. doi: 10.1128/jcm.26.12.2626-2631.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Lazar J. D., Wilner K. D. Drug interactions with fluconazole. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S327–S333. doi: 10.1093/clinids/12.supplement_3.s327. [DOI] [PubMed] [Google Scholar]
  42. McIlroy M. A. Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia, and typhlitis. J Infect Dis. 1991 Feb;163(2):420–421. doi: 10.1093/infdis/163.2.420. [DOI] [PubMed] [Google Scholar]
  43. Meunier F., Aoun M., Gerard M. Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazole. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S364–S368. doi: 10.1093/clinids/12.supplement_3.s364. [DOI] [PubMed] [Google Scholar]
  44. Millon L., Manteaux A., Reboux G., Drobacheff C., Monod M., Barale T., Michel-Briand Y. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol. 1994 Apr;32(4):1115–1118. doi: 10.1128/jcm.32.4.1115-1118.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Ng T. T., Denning D. W. Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach. J Infect. 1993 Mar;26(2):117–125. doi: 10.1016/0163-4453(93)92707-4. [DOI] [PubMed] [Google Scholar]
  46. Odds F. C. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother. 1993 Apr;31(4):463–471. doi: 10.1093/jac/31.4.463. [DOI] [PubMed] [Google Scholar]
  47. Parente F., Ardizzone S., Cernuschi M., Antinori S., Esposito R., Moroni M., Lazzarin A., Bianchi Porro G. Prevention of symptomatic recurrences of esophageal candidiasis in AIDS patients after the first episode: a prospective open study. Am J Gastroenterol. 1994 Mar;89(3):416–420. [PubMed] [Google Scholar]
  48. Parente F., Cernuschi M., Rizzardini G., Lazzarin A., Valsecchi L., Bianchi Porro G. Opportunistic infections of the esophagus not responding to oral systemic antifungals in patients with AIDS: their frequency and treatment. Am J Gastroenterol. 1991 Dec;86(12):1729–1734. [PubMed] [Google Scholar]
  49. Persons D. A., Laughlin M., Tanner D., Perfect J., Gockerman J. P., Hathorn J. W. Fluconazole and Candida krusei fungemia. N Engl J Med. 1991 Oct 31;325(18):1315–1315. [PubMed] [Google Scholar]
  50. Pfaller M. A., Rhine-Chalberg J., Redding S. W., Smith J., Farinacci G., Fothergill A. W., Rinaldi M. G. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol. 1994 Jan;32(1):59–64. doi: 10.1128/jcm.32.1.59-64.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Price M. F., LaRocco M. T., Gentry L. O. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 1994 Jun;38(6):1422–1424. doi: 10.1128/aac.38.6.1422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Redding S., Smith J., Farinacci G., Rinaldi M., Fothergill A., Rhine-Chalberg J., Pfaller M. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis. 1994 Feb;18(2):240–242. doi: 10.1093/clinids/18.2.240. [DOI] [PubMed] [Google Scholar]
  53. Rex J. H., Bennett J. E., Sugar A. M., Pappas P. G., van der Horst C. M., Edwards J. E., Washburn R. G., Scheld W. M., Karchmer A. W., Dine A. P. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994 Nov 17;331(20):1325–1330. doi: 10.1056/NEJM199411173312001. [DOI] [PubMed] [Google Scholar]
  54. Rex J. H., Hanson L. H., Amantea M. A., Stevens D. A., Bennett J. E. Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography. Antimicrob Agents Chemother. 1991 May;35(5):846–850. doi: 10.1128/aac.35.5.846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Rex J. H., Pfaller M. A., Barry A. L., Nelson P. W., Webb C. D. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother. 1995 Jan;39(1):40–44. doi: 10.1128/aac.39.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Rex J. H., Pfaller M. A., Rinaldi M. G., Polak A., Galgiani J. N. Antifungal susceptibility testing. Clin Microbiol Rev. 1993 Oct;6(4):367–381. doi: 10.1128/cmr.6.4.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Reynes J., Mallié M., André D., Janbon F., Bastide J. M. Traitement et prophylaxie secondaire par fluconazole des candidoses oropharyngées des sujets VIH +. Analyse mycologique des echecs. Pathol Biol (Paris) 1992 May;40(5):513–517. [PubMed] [Google Scholar]
  58. Ruhnke M., Eigler A., Engelmann E., Geiseler B., Trautmann M. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection. 1994 Mar-Apr;22(2):132–136. doi: 10.1007/BF01739024. [DOI] [PubMed] [Google Scholar]
  59. Røder B. L., Sonnenschein C., Hartzen S. H. Failure of fluconazole therapy in Candida krusei fungemia. Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):173–173. doi: 10.1007/BF01964453. [DOI] [PubMed] [Google Scholar]
  60. Saag M. S., Dismukes W. E. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988 Jan;32(1):1–8. doi: 10.1128/aac.32.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Sandven P., Bjørneklett A., Maeland A. Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study Group. Antimicrob Agents Chemother. 1993 Nov;37(11):2443–2448. doi: 10.1128/aac.37.11.2443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Sangeorzan J. A., Bradley S. F., He X., Zarins L. T., Ridenour G. L., Tiballi R. N., Kauffman C. A. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med. 1994 Oct;97(4):339–346. doi: 10.1016/0002-9343(94)90300-x. [DOI] [PubMed] [Google Scholar]
  63. Sanguineti A., Carmichael J. K., Campbell K. Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch Intern Med. 1993 May 10;153(9):1122–1124. [PubMed] [Google Scholar]
  64. Siegman-Igra Y., Rabaw M. Y. Failure of fluconazole in systemic candidiasis. Eur J Clin Microbiol Infect Dis. 1992 Feb;11(2):201–202. doi: 10.1007/BF01967082. [DOI] [PubMed] [Google Scholar]
  65. Smith D., Boag F., Midgley J., Gazzard B. Fluconazole resistant candida in AIDS. J Infect. 1991 Nov;23(3):345–346. doi: 10.1016/0163-4453(91)93584-y. [DOI] [PubMed] [Google Scholar]
  66. Smith K. J., Warnock D. W., Kennedy C. T., Johnson E. M., Hopwood V., Van Cutsem J., Vanden Bossche H. Azole resistance in Candida albicans. J Med Vet Mycol. 1986 Apr;24(2):133–144. [PubMed] [Google Scholar]
  67. Soutar R. L. Fluconazole or amphotericin for candidosis in neutropenic patients. Lancet. 1991 Jan 19;337(8734):181–181. doi: 10.1016/0140-6736(91)90851-f. [DOI] [PubMed] [Google Scholar]
  68. Stevens D. A., Greene S. I., Lang O. S. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med. 1991 Dec;151(12):2458–2464. [PubMed] [Google Scholar]
  69. Troillet N., Durussel C., Bille J., Glauser M. P., Chave J. P. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1993 Dec;12(12):911–915. doi: 10.1007/BF01992164. [DOI] [PubMed] [Google Scholar]
  70. Vuffray A., Durussel C., Boerlin P., Boerlin-Petzold F., Bille J., Glauser M. P., Chave J. P. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS. 1994 May;8(5):708–709. doi: 10.1097/00002030-199405000-00023. [DOI] [PubMed] [Google Scholar]
  71. Warnock D. W., Burke J., Cope N. J., Johnson E. M., von Fraunhofer N. A., Williams E. W. Fluconazole resistance in Candida glabrata. Lancet. 1988 Dec 3;2(8623):1310–1310. doi: 10.1016/s0140-6736(88)92919-4. [DOI] [PubMed] [Google Scholar]
  72. White D. J., Johnson E. M., Warnock D. W. Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata. Genitourin Med. 1993 Apr;69(2):112–114. doi: 10.1136/sti.69.2.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Willocks L., Leen C. L., Brettle R. P., Urquhart D., Russell T. B., Milne L. J. Fluconazole resistance in AIDS patients. J Antimicrob Chemother. 1991 Dec;28(6):937–939. doi: 10.1093/jac/28.6.937. [DOI] [PubMed] [Google Scholar]
  74. Wingard J. R., Merz W. G., Rinaldi M. G., Johnson T. R., Karp J. E., Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991 Oct 31;325(18):1274–1277. doi: 10.1056/NEJM199110313251803. [DOI] [PubMed] [Google Scholar]
  75. Wingard J. R., Merz W. G., Rinaldi M. G., Miller C. B., Karp J. E., Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother. 1993 Sep;37(9):1847–1849. doi: 10.1128/aac.37.9.1847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. vanden Bossche H., Marichal P., Odds F. C., Le Jeune L., Coene M. C. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother. 1992 Dec;36(12):2602–2610. doi: 10.1128/aac.36.12.2602. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES